| News

RocketVax secures partners for coronavirus vaccine in Basel

17.06.2021

RocketVax has found cooperation partners for the development of its innovative coronavirus vaccine. The University Hospital of Basel, the University of Basel and the Swiss Tropical and Public Health Institute are providing funding, research infrastructure and staff resources.

The University Hospital of Basel (USB), the University of Basel and the Swiss Tropical and Public Health Institute (Swiss TPH) are entering into a research cooperation with RocketVax. All four are based in Basel. Founded a year ago, the startup is developing a next-generation vaccine against COVID-19. It reportedly induces a long-lasting immune response and works more effectively against mutations. “The Basel region offers the requisite expertise and innovative ideas for further developing the vaccine,” the USB explained in a press release. “The research partners are exploiting this potential to now open a ‘window of opportunity’.”

Through seed funding of 1 million Swiss francs, the USB is enabling the preclinical research work on the vaccine that has already begun to continue. The University of Basel and the Swiss TPH are contributing their research infrastructure and staff resources to the project. The Canton of Basel-Stadt is supporting the research cooperation with a further 1 million francs. According to the USB, Switzerland and other countries stand to benefit from a vaccine made in the Basel region. The first six-month project phase was backed by Innosuisse, through funding of 1.2 million francs.

The RocketVax vaccine uses coronavirus-based vectors. Different to first-generation vaccines that only target the spike protein, it is above all characterized by the fact that it activates multiple lines of immune system defense to combat the SARS-CoV-2 virus. The aim here is to provoke a much broader antibody reaction and to reduce risks connected with viral escape mechanisms. The designed genome lacks one essential virus element needed for replication, meaning it is not infectious.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Ontotext opens new office in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Ontotext opens new office in the Basel Area

Ontotext, a company based in New York City and the Bulgarian capital of Sofia, has opened a new location at...

Read More
Owkin heads to Basel
Basel Area Business & Innovation, Innovation, Invest

Owkin heads to Basel

The Franco-US startup Owkin is establishing a branch office in Basel. The company develops solutions for the life sciences industry...

Read More
Danish AI company settling in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Danish AI company settling in the Basel Area

Abzu has settled on the Novartis Campus of the Switzerland Innovation Park Basel Area. From there, the Danish deep tech...

Read More
«I always wanted to create something from scratch»
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

«I always wanted to create something from scratch»

Already when he was young, he was driven to create and invent. Today at the age of 33, Gwenael Hannema...

Read More
The i4Challenge announces the winners of 2021
Basel Area Business & Innovation, Innovation

The i4Challenge announces the winners of 2021

The i4Challenge shines a light on companies and innovators who help to facilitate the industrial transformation. We present the winners...

Read More
Basel Area becomes the Swiss hotspot for Chinese pharma companies
Basel Area Business & Innovation, Innovation, Invest

Basel Area becomes the Swiss hotspot for Chinese pharma companies

More and more Chinese pharmaceutical companies are choosing the Basel Area as location for their subsidiary in Switzerland. Among them...

Read More
1 2 3 18

Do you have a question? We'd like to hear from you.